
TRML Stock Forecast & Price Target
TRML Analyst Ratings
Bulls say
Tourmaline Bio Inc has demonstrated a robust stock performance, with shares increasing over 30% since their launch, significantly outperforming the biotech index. The company's estimated market value has risen to $1.29 billion, indicating a strong financial standing, while the potential revenue from international markets could lead to an increased valuation of approximately $53 per share, driven by promising clinical data. Furthermore, the company's initial product candidate, TOUR006, shows potential for a competitive advantage in treating life-altering immune diseases, particularly by addressing cardiovascular risk profiles, which adds to the overall positive outlook for the stock.
Bears say
Tourmaline Bio Inc has experienced significant stock underperformance, with shares declining by 35% year-to-date in 2025 compared to a modest 1% return for the NASDAQ Biotechnology Index. The company's financial outlook remains precarious, with a net loss of $73.2 million reported for 2024 and potential valuations dropping to as low as $10 per share in a worst-case scenario involving the termination of its product candidate pacibekitug. Additionally, concerns regarding the efficacy of pacibekitug in the ASCVD space, particularly in light of competitor data, further exacerbate the financial risks faced by the company.
This aggregate rating is based on analysts' research of Tourmaline Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
TRML Analyst Forecast & Price Prediction
Start investing in TRML
Order type
Buy in
Order amount
Est. shares
0 shares